A billion-dollar bet on schizophrenia genetics is starting to pay off

In the late 1990s, Ted and Vada Stanley watched their son Jonathan struggle with severe bipolar disorder during college. Jonathan eventually stabilized on lithium - a drug first used for psychiatric patients in 1949. The Stanleys were struck by a grim realization: in half a century, treatment options had barely advanced. They decided to do something about it, placing what would become one of the largest philanthropic bets in the history of biomedical research.

The long road from frustration to genetics

The Stanleys' partnership with the Broad Institute began in 2007 with a hypothesis that was, at the time, more hope than evidence: human genetics would be the key to understanding psychiatric conditions and designing new treatments. Schizophrenia and bipolar disorder had resisted biological explanation for decades. Unlike cancer or heart disease, where molecular mechanisms had been productively targeted by drugs, the most devastating psychiatric conditions remained biologically opaque.

The Stanley Center for Psychiatric Research launched with the mission of changing that. Nearly two decades and now more than $1 billion later - including a new $280 million commitment announced this month - the science is reaching a turning point.

What the money built

The scale of what the Stanley Center has assembled is unusual in academic research. More than 100 scientists work across human genetics, computational biology, neurobiology, stem cell biology, chemistry, and clinical psychiatry. The center has built and manages the world's largest collection of genetic data for psychiatric research, organized through international consortia that share samples and analysis across institutions.

Two consortia led by Stanley Center researchers have been particularly productive. The SCHEMA consortium (Schizophrenia Exome Sequencing Meta-analysis) has collected samples from 143,000 individuals and analyzed DNA from 75,000 of them. The BipEx consortium (Bipolar Exome) has done parallel work for bipolar disorder.

From genome scans to specific genes

The scientific milestones have accelerated. In 2014, researchers from the Stanley Center and collaborators published the largest genomic study of any psychiatric disorder at that time, studying more than 150,000 people and identifying over 100 locations in the human genome associated with schizophrenia risk.

In 2016, a landmark study dug into those genetic signals and identified a specific mechanism: variants in C4, an immune system gene involved in synaptic pruning - the process by which the brain eliminates unnecessary neural connections during development. The finding connected schizophrenia risk to a concrete biological process for the first time. The acting director of the National Institute of Mental Health at the time described it as a crucial turning point.

By 2022, larger cohorts and genome sequencing had identified additional genes for schizophrenia and the first strong genetic risk factor for bipolar disorder. The catalog of validated risk genes continues to grow, and each one represents a potential entry point for therapeutic development.

The translation challenge

Identifying genes is necessary but not sufficient. Schizophrenia and bipolar disorder are polygenic conditions - influenced by many genetic variants, each contributing small effects. There is no single "schizophrenia gene" to target. The path from genetic discovery to drug development requires understanding which genes converge on which biological pathways, which cell types are affected, and which molecular targets are druggable.

The Stanley Center is now building the infrastructure for that translation. Research teams are developing stem cell and animal models based on human genetic findings, using them to study specific pathways and test chemical perturbations. Advanced spatial profiling tools are mapping which cells and brain regions are associated with psychiatric risk genes. And the center is actively pursuing industry partnerships and internal drug discovery projects.

No drugs have yet emerged from this work. Schizophrenia remains a leading cause of mortality in young people, and existing treatments target symptoms rather than underlying biology. The gap between genetic insight and clinical impact is real, and closing it will take years of additional work.

A new model for research philanthropy

The Stanley family's approach represents something distinctive in science funding. Most philanthropic gifts to biomedical research are relatively small and distributed across many projects. The Stanleys concentrated more than $1 billion into a single institution pursuing a single strategic hypothesis - that genetics would unlock psychiatric disease biology. The bet required patience: the payoffs were not measured in years but in decades.

Whether the approach ultimately delivers new treatments remains to be seen. But the field it helped create is real. Psychiatric genetics, which barely existed as a discipline when the Stanley Center launched, is now a vibrant global enterprise. The tools, datasets, and collaborative networks the center built are used by researchers worldwide. That infrastructure will persist regardless of what any individual drug program produces.

Jonathan Stanley, now managing his bipolar disorder, described his parents' vision: a world where psychiatric conditions are treated with the same molecular precision as cancer and heart disease. The new funding commitment signals that the family believes the science is close enough to that vision to warrant another major push.